Eva Rohde, MD, Medical University Salzburg, Salzburg, Austria, describes ongoing research evaluating the therapeutic potential of the vesicular secretome fraction (VSF) in hearing loss. A single patient with Meniere’s disease, a condition of the inner ear, received a co-injection of VSF in one ear during surgical cochlear implantation, which resulted in a slight improvement in cochlear electrode function and no short- or long-term adverse events. The initiation of a Phase I safety clinical trial is pending, depending on the outcomes of ongoing pre-clinical safety testing, including biodistribution and toxicology assays. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.
Eva Rohde is CEO of PMU Innovations GmbH., Salzburg, Austria. Eva Rohde is a Medical Consultant of MDimune Inc., Seoul, Korea.